HER3-DXd demonstrated to inhibit tumor growth in HER3+, EGFR-mutated, EGFR-TKI resistant patient-derived xenograft (PDX) models, while it was ineffective in HER3-negative models [79]. This evidence concerns the gene EGFR and neoplasm.